MX341066B - Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una enfermedad parasitaria. - Google Patents

Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una enfermedad parasitaria.

Info

Publication number
MX341066B
MX341066B MX2012005522A MX2012005522A MX341066B MX 341066 B MX341066 B MX 341066B MX 2012005522 A MX2012005522 A MX 2012005522A MX 2012005522 A MX2012005522 A MX 2012005522A MX 341066 B MX341066 B MX 341066B
Authority
MX
Mexico
Prior art keywords
source
parasitic disease
diagnostic
vaccine
parasitic
Prior art date
Application number
MX2012005522A
Other languages
English (en)
Other versions
MX2012005522A (es
Inventor
Soto Alvarez Manuel
Alonso Bedate Carlos
Ramirez Garcia Laura
Original Assignee
Laboratorios Leti S L *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Leti S L * filed Critical Laboratorios Leti S L *
Publication of MX2012005522A publication Critical patent/MX2012005522A/es
Publication of MX341066B publication Critical patent/MX341066B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a composición que comprende una fuente de L3 y/o L5 y opcionalmente un adyuvante para la preparación de una medicina para el tratamiento o prevención de una enfermedad parasitaria y su uso en el diagnóstico de dicha enfermedad parasitaria.
MX2012005522A 2009-11-13 2010-11-12 Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una enfermedad parasitaria. MX341066B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26102009P 2009-11-13 2009-11-13
EP09175929 2009-11-13
PCT/EP2010/067380 WO2011058137A1 (en) 2009-11-13 2010-11-12 The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease

Publications (2)

Publication Number Publication Date
MX2012005522A MX2012005522A (es) 2012-09-28
MX341066B true MX341066B (es) 2016-08-05

Family

ID=42060726

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012005522A MX341066B (es) 2009-11-13 2010-11-12 Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una enfermedad parasitaria.

Country Status (26)

Country Link
US (1) US10604551B2 (es)
EP (2) EP2499158B1 (es)
JP (1) JP5875987B2 (es)
KR (1) KR101881947B1 (es)
CN (2) CN107551264B (es)
AP (1) AP3464A (es)
AR (1) AR080621A1 (es)
AU (1) AU2010317962B2 (es)
BR (1) BR112012011395B1 (es)
CA (1) CA2780740C (es)
CO (1) CO6551684A2 (es)
CY (1) CY1118402T1 (es)
EA (1) EA022221B1 (es)
EC (1) ECSP12011951A (es)
ES (1) ES2612786T3 (es)
HR (1) HRP20170176T1 (es)
IL (1) IL219770A (es)
MA (1) MA33813B1 (es)
MX (1) MX341066B (es)
PE (1) PE20121553A1 (es)
PH (1) PH12012500942A1 (es)
PT (1) PT2499158T (es)
SA (1) SA110310855B1 (es)
TN (1) TN2012000217A1 (es)
WO (1) WO2011058137A1 (es)
ZA (1) ZA201203516B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
CN103270048B (zh) * 2010-11-10 2016-11-23 热体实验室有限公司 新型佐剂
SG194850A1 (en) * 2011-05-09 2013-12-30 Leti Sl Lab Molecule for treating an inflammatory disorder
WO2015001383A1 (en) * 2013-07-02 2015-01-08 Institut De Recherche Pour Le Developpement Peptides and methods for the detection of leishmaniasis
US10973897B2 (en) * 2016-04-14 2021-04-13 Peptcell Limited Chagas antigens and antibodies and compositions, methods and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
ES2273519T3 (es) 1998-12-23 2007-05-01 C.B.F. Leti S.A. Gen quimerico que codifica los determinantes antigenicos de cuatro proteinas de l. infantum.
FR2826018B1 (fr) * 2001-06-18 2005-01-07 Pasteur Institut Tunis Gene associe a la virulence du parasite leishmania
WO2003047602A1 (en) 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
JP4662925B2 (ja) 2003-04-23 2011-03-30 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 改善された効率を有する結核ワクチン
KR100992646B1 (ko) 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
RS52507B (sr) 2003-11-05 2013-04-30 Laboratorios Leti S.L. Primena specifičnih histona za lečenje parazitnih bolesti
CA2540736A1 (en) * 2005-04-08 2006-10-08 Institut Pasteur Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof
CN101466831A (zh) * 2006-04-10 2009-06-24 传染病研究所有限公司 用于诊断和治疗利什曼病的化合物和方法
EP2170372A1 (en) * 2007-07-13 2010-04-07 Infectious Disease Research Institute Leishmania sterol 24-c-methyltransferase compositions for the prevention, treatment and diagnosis of leishmaniasis
AP3007A (en) * 2008-01-18 2014-10-31 Leti Sl Lab Vaccine comprising a ribosomal protein extract (RPE) and optionally a thi-promoting adjuvant
RU2558233C2 (ru) * 2009-07-13 2015-07-27 Лабораториос Лети, С.Л. Диагностика паразитарного заболевания, такого как лейшманиоз, с использованием экстракта рибосомальных белков (rpe)
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي

Also Published As

Publication number Publication date
ES2612786T3 (es) 2017-05-18
ZA201203516B (en) 2013-01-31
PE20121553A1 (es) 2012-12-13
MA33813B1 (fr) 2012-12-03
EA022221B1 (ru) 2015-11-30
KR20120104567A (ko) 2012-09-21
CN107551264B (zh) 2021-05-11
CN102712684A (zh) 2012-10-03
US20120263746A1 (en) 2012-10-18
KR101881947B1 (ko) 2018-07-26
AU2010317962A1 (en) 2012-06-21
EP2499158A1 (en) 2012-09-19
TN2012000217A1 (en) 2013-12-12
PT2499158T (pt) 2017-01-24
JP5875987B2 (ja) 2016-03-02
AP2012006275A0 (en) 2012-06-30
CA2780740A1 (en) 2011-05-19
US10604551B2 (en) 2020-03-31
HK1176074A1 (en) 2013-07-19
AP3464A (en) 2015-11-30
EA201290319A1 (ru) 2012-12-28
SA110310855B1 (ar) 2014-09-16
AR080621A1 (es) 2012-04-25
HRP20170176T1 (hr) 2017-04-07
BR112012011395B1 (pt) 2022-03-03
CO6551684A2 (es) 2012-10-31
CN107551264A (zh) 2018-01-09
EP3101028A1 (en) 2016-12-07
EP2499158B1 (en) 2016-11-02
CA2780740C (en) 2019-08-20
IL219770A0 (en) 2012-07-31
BR112012011395A2 (pt) 2020-09-01
PH12012500942A1 (en) 2013-01-07
ECSP12011951A (es) 2012-07-31
JP2013510823A (ja) 2013-03-28
MX2012005522A (es) 2012-09-28
IL219770A (en) 2017-10-31
CY1118402T1 (el) 2017-06-28
AU2010317962B2 (en) 2014-09-18
WO2011058137A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
IN2012DN02736A (es)
MX364200B (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
MX347471B (es) Vacunas que comprenden colesterol y cpg como moleculas portadoras-adyuvantes unicas.
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
SG178954A1 (en) Immunogenic compositions including tlr activity modulators
IN2014MN00948A (es)
MX2012007098A (es) Derivados fenolicos y su uso farmaceutico o cosmetico.
MX2019003249A (es) Diagnostico, prevencion y tratamiento de enfermedades de la articulacion.
EP2415763A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF GLAUCOMA
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
SG179082A1 (en) Method for the preparation of an influenza virus
GB2483419B (en) Formulations for the treatment of deep tissue pain
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
TN2012000217A1 (en) The use of an l3 and/or l5 source as a vaccine or as a diagnostic for a parasitic disease
WO2012116992A3 (en) Oral use of a composition comprising steviol or isosteviol
MX361456B (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una enfermedad parasitaria.
TN2010000338A1 (en) Vaccine comprising a ribosomal protein extract (rpe) and optionally a th1-promoting adjuvant
WO2013093629A3 (en) Modular vaccines, methods and compositions related thereto
WO2011002423A3 (en) Solubility enhancing pharmaceutical composition
TH149179A (th) องค์ประกอบทางเภสัชกรรม, รูปแบบเภสัชภัณฑ์, กระบวนการในการเตรียมองค์ประกอบ และรูปแบบดังกล่าว, วิธีการในการรักษา และการใช้องค์ประกอบและรูปแบบดังกล่าว
HU0800083D0 (en) Pharmaceutical compositions for the treatment and prevention of tumorous diseases

Legal Events

Date Code Title Description
FG Grant or registration